Navigation Links
RQx Pharmaceuticals and Genentech Enter Drug Discovery Collaboration to Develop Novel Drug Compounds
Date:2/12/2013

LA JOLLA, Calif., Feb. 12, 2013 /PRNewswire/ -- RQx Pharmaceuticals, Inc. today announced that it has entered into a drug discovery collaboration with Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), for the discovery and development of novel drug compounds for an undisclosed target. Under the terms of the agreement, RQx will receive an up-front payment and is eligible to receive research and development milestone payments totaling $111 million.  In addition, RQx is eligible to receive royalties on sales of products resulting from the collaboration.

"We have made tremendous progress at RQx since the company's founding two years ago, and we are pleased to be moving forward in partnership with Genentech to bring new drugs to market," said Court Turner, CEO of RQx and venture partner at Avalon Ventures.

RQx Pharmaceuticals was founded by Avalon Ventures in 2010 with Floyd Romesberg , Ph.D., a professor at The Scripps Research Institute (La Jolla, CA) and two former graduate students of the Romesberg Lab.  Avalon Ventures formed the company, then seeded and led the Company's Series A financing, which also included an investment from Correlation Ventures. 

"We see a unique opportunity to apply Genentech's expertise in drug discovery and development with the innovation and focus of RQx, to develop a new class of novel drug compounds," said James Sabry , senior vice president of partnering at Genentech.

About RxQ Pharmaceuticals, Inc.

RQx Pharmaceuticals is a biopharmaceutical company developing broad-spectrum small molecule antibiotics to combat serious life threatening infections, including those caused by multi drug-resistant Gram-negative bacteria. To address the growing threat of MDR bacteria, RQx is developing novel, first-in-class antibiotics that evade the current abundance of antibiotic resistance mechanisms, which are now common across the globe.  RQx is inspired by the synergies possible when combining naturally produced antibiotics with modern medical chemistry capabilities and is focused on identifying ideal target/inhibitor combinations to deliver a pipeline of novel antibiotic candidates.


'/>"/>
SOURCE RQx Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Vanda Pharmaceuticals Reports Fourth Quarter 2012 and Full Year 2012 Results
2. Jazz Pharmaceuticals To Report 2012 Fourth Quarter And Full Year Financial Results On February 26, 2013
3. DelMar Pharmaceuticals Announces $1.0 Million Third Closing in Private Placement
4. Perrigo Company Acquires U.K.-based Rosemont Pharmaceuticals Ltd. For Approximately £180 Million Or $283 Million
5. Inovio Pharmaceuticals, Inc. Investor Presentation Now Available for On-demand Viewing at RetailInvestorConferences.com
6. Imprimis Pharmaceuticals Announces Pricing of Public Offering of 1,840,000 Shares of Common Stock
7. Anthera Pharmaceuticals to Present at the 2013 Leerink Global Healthcare Conference
8. Avanir Pharmaceuticals Reports Fiscal 2013 First Quarter Financial And Business Results
9. Shares of Oramed Pharmaceuticals Are Approved for Listing on the Nasdaq Capital Market
10. Avanir Pharmaceuticals Announces Positive Interim Data From Pharmacokinetic Study With Next Generation Compound AVP-786
11. Optimer Pharmaceuticals to Host Conference Call and Webcast to Discuss Fourth Quarter and Fiscal Year 2012 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/24/2017)... -- GenomeDx Biosciences today announced that six abstracts featuring Decipher ... Classifier tests will be presented at the 32 nd ... March 24 to 28, 2017 in London, ... Europe,s largest urological event showcasing the ... The abstract titled "Muscle invasive bladder cancer: ...
(Date:3/24/2017)... GENEVA , March 24, 2017 ... efforts to develop sutezolid as effective response to infectious ... TB Alliance and the Medicines Patent Pool (MPP) announced ... an antibiotic drug candidate which demonstrated encouraging results in ... sutezolid in combination with other TB drugs and follows ...
(Date:3/23/2017)... -- Research and Markets has announced the addition of ... Procedure By Technique, Repair Procedure By Technique, By Region, By Country ... ... to grow at a CAGR of 13.35% during 2016-2021 ... aging population, growth in population with heart disease and rising advances ...
Breaking Medicine Technology:
(Date:3/24/2017)... ... March 24, 2017 , ... The iaedp Foundation, the premier provider ... caring for those suffering from the full spectrum of disordered eating, announced today that ... professionals from nearly all 50 states and several countries converged on the Green Valley ...
(Date:3/24/2017)... ... March 24, 2017 , ... Shamanic healer and teacher Anahata ... and Spiritual Awakening, proudly presents her Sacred Peru retreat with world famous ... spiritual journey during the Summer Solstice will also be her final international retreat, ...
(Date:3/24/2017)... PA (PRWEB) , ... March 24, 2017 , ... ... Oncology Nursing Society (ONS) wanted to create a communications platform that positions them ... this goal, Elliance and ONS reinvented their online publication as an always-on, always-fresh ...
(Date:3/24/2017)... (PRWEB) , ... March 24, 2017 , ... ... two panels at the Advanced ERISA Benefit Claims Litigation seminar in Chicago, Illinois. ... the Administrative Record, The majority of cases litigated under ERISA involve claims for ...
(Date:3/24/2017)... ... ... Viewers who like to educate themselves on current issues and who enjoy ... societal issues tend to appreciate and love the "Informed" series, hosted by Rob Lowe. ... for causes around the world. , Running for charity has become a ...
Breaking Medicine News(10 mins):